Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Cross Teams Up With MacroGenics For Bio-better Of Roche's Herceptin

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Green Cross has signed an agreement with Rockville, Maryland-based MacroGenics to develop and sell the latter's modified anti-breast cancer monoclonal antibody MGAH22 in Korea. MGAH22 is a modified "bio-better" of Roche's oncology agent Herceptin (trastuzumab)
Advertisement

Related Content

Nanotek Biologics Deal Gives Green Cross Route To Russia
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
Advertisement
UsernamePublicRestriction

Register

SC075805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel